| [ |
| { |
| "patient_id": "ANODE_SYNTH_2025_001", |
| "cancer_type": "Non-small cell lung cancer", |
| "histology": "Adenocarcinoma", |
| "stage_at_diagnosis": "IV", |
| "molecular_profile": { |
| "driver_mutation": "KRAS G12C", |
| "t790m_resistance": null, |
| "tumor_mutational_burden_mut_Mb": 15.1, |
| "microsatellite_status": "MSS", |
| "pd_l1_tps_percent": 11 |
| }, |
| "baseline_clinical": { |
| "age": 76, |
| "sex": "female", |
| "bmi": 22.5, |
| "smoking_pack_years": 39, |
| "ecog_performance_status": 0, |
| "comorbidities": [ |
| "hypertension", |
| "diabetes" |
| ] |
| }, |
| "disease_burden_at_dx": { |
| "primary_tumor_size_cm": 4.0, |
| "metastatic_sites": [ |
| "pleura", |
| "brain", |
| "bone" |
| ], |
| "brain_metastases_present": false, |
| "radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease." |
| }, |
| "treatment_course": { |
| "first_line_therapy": { |
| "regimen": "sotorasib 960 mg daily", |
| "start_date": "2025-01-28", |
| "best_response": "Partial response", |
| "radiologic_response": { |
| "first_ct_8wk_change_percent": -46, |
| "peak_response_20wk_change_percent": -73 |
| }, |
| "pfs_months": 18 |
| }, |
| "second_line_therapy": { |
| "trigger_reason": "symptomatic progression", |
| "regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab", |
| "start_date": "2026-05-29", |
| "best_response": "Stable disease", |
| "toxicity_grade": [ |
| "Grade 2 fatigue", |
| "none" |
| ] |
| } |
| }, |
| "survival_outcomes": { |
| "overall_survival_months": 67, |
| "censored": true |
| }, |
| "longitudinal_labs": [ |
| { |
| "date": "2024-12-03", |
| "hemoglobin_g_dL": 13.0, |
| "wbc_k_uL": 8.2, |
| "platelets_k_uL": 349, |
| "creatinine_mg_dL": 1.1, |
| "alt_U_L": 39 |
| }, |
| { |
| "date": "2025-07-27", |
| "hemoglobin_g_dL": 12.3, |
| "wbc_k_uL": 8.4, |
| "platelets_k_uL": 171, |
| "creatinine_mg_dL": 0.94, |
| "alt_U_L": 118 |
| }, |
| { |
| "date": "2026-05-29", |
| "hemoglobin_g_dL": 12.5, |
| "wbc_k_uL": 4.0, |
| "platelets_k_uL": 251, |
| "creatinine_mg_dL": 1.43, |
| "alt_U_L": 184 |
| } |
| ], |
| "synthetic_high_fidelity": true |
| }, |
| { |
| "patient_id": "ANODE_SYNTH_2025_002", |
| "cancer_type": "Non-small cell lung cancer", |
| "histology": "Squamous cell", |
| "stage_at_diagnosis": "IV", |
| "molecular_profile": { |
| "driver_mutation": "None (PD-L1 high)", |
| "t790m_resistance": null, |
| "tumor_mutational_burden_mut_Mb": 11.8, |
| "microsatellite_status": "MSS", |
| "pd_l1_tps_percent": 53 |
| }, |
| "baseline_clinical": { |
| "age": 69, |
| "sex": "female", |
| "bmi": 30.2, |
| "smoking_pack_years": 32, |
| "ecog_performance_status": 1, |
| "comorbidities": [ |
| "diabetes", |
| "hyperlipidemia" |
| ] |
| }, |
| "disease_burden_at_dx": { |
| "primary_tumor_size_cm": 5.8, |
| "metastatic_sites": [ |
| "liver", |
| "brain", |
| "contralateral lung" |
| ], |
| "brain_metastases_present": false, |
| "radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease." |
| }, |
| "treatment_course": { |
| "first_line_therapy": { |
| "regimen": "pembrolizumab 200 mg q3w", |
| "start_date": "2024-02-04", |
| "best_response": "Partial response", |
| "radiologic_response": { |
| "first_ct_8wk_change_percent": -48, |
| "peak_response_20wk_change_percent": -78 |
| }, |
| "pfs_months": 10 |
| }, |
| "second_line_therapy": { |
| "trigger_reason": "new brain metastases", |
| "regimen": "docetaxel 75 mg/m\u00b2 q21d", |
| "start_date": "2025-04-21", |
| "best_response": "Stable disease", |
| "toxicity_grade": [ |
| "Grade 1 nausea", |
| "none" |
| ] |
| } |
| }, |
| "survival_outcomes": { |
| "overall_survival_months": 30, |
| "censored": true |
| }, |
| "longitudinal_labs": [ |
| { |
| "date": "2024-01-15", |
| "hemoglobin_g_dL": 14.0, |
| "wbc_k_uL": 5.2, |
| "platelets_k_uL": 439, |
| "creatinine_mg_dL": 0.91, |
| "alt_U_L": 53 |
| }, |
| { |
| "date": "2024-08-02", |
| "hemoglobin_g_dL": 10.8, |
| "wbc_k_uL": 5.1, |
| "platelets_k_uL": 187, |
| "creatinine_mg_dL": 1.15, |
| "alt_U_L": 36 |
| }, |
| { |
| "date": "2025-04-21", |
| "hemoglobin_g_dL": 9.7, |
| "wbc_k_uL": 5.6, |
| "platelets_k_uL": 179, |
| "creatinine_mg_dL": 1.94, |
| "alt_U_L": 36 |
| } |
| ], |
| "synthetic_high_fidelity": true |
| }, |
| { |
| "patient_id": "ANODE_SYNTH_2025_003", |
| "cancer_type": "Non-small cell lung cancer", |
| "histology": "Adenocarcinoma", |
| "stage_at_diagnosis": "IVB", |
| "molecular_profile": { |
| "driver_mutation": "EGFR exon 19 deletion", |
| "t790m_resistance": false, |
| "tumor_mutational_burden_mut_Mb": 11.8, |
| "microsatellite_status": "MSS", |
| "pd_l1_tps_percent": 2 |
| }, |
| "baseline_clinical": { |
| "age": 78, |
| "sex": "female", |
| "bmi": 35.6, |
| "smoking_pack_years": 0, |
| "ecog_performance_status": 1, |
| "comorbidities": [] |
| }, |
| "disease_burden_at_dx": { |
| "primary_tumor_size_cm": 5.2, |
| "metastatic_sites": [ |
| "bone", |
| "contralateral lung" |
| ], |
| "brain_metastases_present": false, |
| "radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present." |
| }, |
| "treatment_course": { |
| "first_line_therapy": { |
| "regimen": "osimertinib 80 mg orally once daily", |
| "start_date": "2021-03-21", |
| "best_response": "Partial response", |
| "radiologic_response": { |
| "first_ct_8wk_change_percent": -13, |
| "peak_response_20wk_change_percent": -30 |
| }, |
| "pfs_months": 27 |
| }, |
| "second_line_therapy": { |
| "trigger_reason": "radiologic progression", |
| "regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab", |
| "start_date": "2022-12-27", |
| "best_response": "Stable disease", |
| "toxicity_grade": [ |
| "none", |
| "Grade 3 neutropenia" |
| ] |
| } |
| }, |
| "survival_outcomes": { |
| "overall_survival_months": 38, |
| "censored": true |
| }, |
| "longitudinal_labs": [ |
| { |
| "date": "2021-02-16", |
| "hemoglobin_g_dL": 12.6, |
| "wbc_k_uL": 4.6, |
| "platelets_k_uL": 274, |
| "creatinine_mg_dL": 0.89, |
| "alt_U_L": 14 |
| }, |
| { |
| "date": "2021-09-17", |
| "hemoglobin_g_dL": 12.4, |
| "wbc_k_uL": 6.8, |
| "platelets_k_uL": 142, |
| "creatinine_mg_dL": 1.21, |
| "alt_U_L": 99 |
| }, |
| { |
| "date": "2022-12-27", |
| "hemoglobin_g_dL": 10.5, |
| "wbc_k_uL": 4.7, |
| "platelets_k_uL": 268, |
| "creatinine_mg_dL": 1.5, |
| "alt_U_L": 97 |
| } |
| ], |
| "synthetic_high_fidelity": true |
| }, |
| { |
| "patient_id": "ANODE_SYNTH_2025_004", |
| "cancer_type": "Non-small cell lung cancer", |
| "histology": "Adenocarcinoma", |
| "stage_at_diagnosis": "IVB", |
| "molecular_profile": { |
| "driver_mutation": "ALK fusion", |
| "t790m_resistance": null, |
| "tumor_mutational_burden_mut_Mb": 4.7, |
| "microsatellite_status": "MSS", |
| "pd_l1_tps_percent": 21 |
| }, |
| "baseline_clinical": { |
| "age": 53, |
| "sex": "male", |
| "bmi": 22.1, |
| "smoking_pack_years": 0, |
| "ecog_performance_status": 1, |
| "comorbidities": [ |
| "diabetes" |
| ] |
| }, |
| "disease_burden_at_dx": { |
| "primary_tumor_size_cm": 3.4, |
| "metastatic_sites": [ |
| "contralateral lung", |
| "brain" |
| ], |
| "brain_metastases_present": false, |
| "radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present." |
| }, |
| "treatment_course": { |
| "first_line_therapy": { |
| "regimen": "alectinib 600 mg BID", |
| "start_date": "2025-08-29", |
| "best_response": "Partial response", |
| "radiologic_response": { |
| "first_ct_8wk_change_percent": -26, |
| "peak_response_20wk_change_percent": -68 |
| }, |
| "pfs_months": 20 |
| }, |
| "second_line_therapy": { |
| "trigger_reason": "radiologic progression", |
| "regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab", |
| "start_date": "2028-01-24", |
| "best_response": "Stable disease", |
| "toxicity_grade": [ |
| "Grade 2 fatigue", |
| "Grade 3 neutropenia" |
| ] |
| } |
| }, |
| "survival_outcomes": { |
| "overall_survival_months": 32, |
| "censored": false |
| }, |
| "longitudinal_labs": [ |
| { |
| "date": "2025-08-04", |
| "hemoglobin_g_dL": 13.1, |
| "wbc_k_uL": 9.1, |
| "platelets_k_uL": 252, |
| "creatinine_mg_dL": 0.67, |
| "alt_U_L": 69 |
| }, |
| { |
| "date": "2026-02-25", |
| "hemoglobin_g_dL": 13.9, |
| "wbc_k_uL": 7.8, |
| "platelets_k_uL": 229, |
| "creatinine_mg_dL": 1.12, |
| "alt_U_L": 58 |
| }, |
| { |
| "date": "2028-01-24", |
| "hemoglobin_g_dL": 10.4, |
| "wbc_k_uL": 4.9, |
| "platelets_k_uL": 137, |
| "creatinine_mg_dL": 1.86, |
| "alt_U_L": 178 |
| } |
| ], |
| "synthetic_high_fidelity": true |
| }, |
| { |
| "patient_id": "ANODE_SYNTH_2025_005", |
| "cancer_type": "Non-small cell lung cancer", |
| "histology": "Adenocarcinoma", |
| "stage_at_diagnosis": "IVB", |
| "molecular_profile": { |
| "driver_mutation": "EGFR L858R", |
| "t790m_resistance": false, |
| "tumor_mutational_burden_mut_Mb": 17.0, |
| "microsatellite_status": "MSS", |
| "pd_l1_tps_percent": 15 |
| }, |
| "baseline_clinical": { |
| "age": 57, |
| "sex": "female", |
| "bmi": 25.8, |
| "smoking_pack_years": 0, |
| "ecog_performance_status": 1, |
| "comorbidities": [] |
| }, |
| "disease_burden_at_dx": { |
| "primary_tumor_size_cm": 7.6, |
| "metastatic_sites": [ |
| "brain", |
| "contralateral lung", |
| "bone" |
| ], |
| "brain_metastases_present": false, |
| "radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease." |
| }, |
| "treatment_course": { |
| "first_line_therapy": { |
| "regimen": "osimertinib 80 mg orally once daily", |
| "start_date": "2025-12-14", |
| "best_response": "Partial response", |
| "radiologic_response": { |
| "first_ct_8wk_change_percent": -48, |
| "peak_response_20wk_change_percent": -70 |
| }, |
| "pfs_months": 36 |
| }, |
| "second_line_therapy": { |
| "trigger_reason": "new brain metastases", |
| "regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab", |
| "start_date": "2028-03-10", |
| "best_response": "Stable disease", |
| "toxicity_grade": [ |
| "Grade 3 neutropenia", |
| "none" |
| ] |
| } |
| }, |
| "survival_outcomes": { |
| "overall_survival_months": 72, |
| "censored": false |
| }, |
| "longitudinal_labs": [ |
| { |
| "date": "2025-11-11", |
| "hemoglobin_g_dL": 13.3, |
| "wbc_k_uL": 5.8, |
| "platelets_k_uL": 321, |
| "creatinine_mg_dL": 0.64, |
| "alt_U_L": 72 |
| }, |
| { |
| "date": "2026-06-12", |
| "hemoglobin_g_dL": 12.4, |
| "wbc_k_uL": 6.9, |
| "platelets_k_uL": 140, |
| "creatinine_mg_dL": 1.59, |
| "alt_U_L": 41 |
| }, |
| { |
| "date": "2028-03-10", |
| "hemoglobin_g_dL": 9.8, |
| "wbc_k_uL": 7.1, |
| "platelets_k_uL": 133, |
| "creatinine_mg_dL": 1.33, |
| "alt_U_L": 112 |
| } |
| ], |
| "synthetic_high_fidelity": true |
| }, |
| { |
| "patient_id": "ANODE_SYNTH_2025_006", |
| "cancer_type": "Non-small cell lung cancer", |
| "histology": "Adenocarcinoma", |
| "stage_at_diagnosis": "IV", |
| "molecular_profile": { |
| "driver_mutation": "KRAS G12C", |
| "t790m_resistance": null, |
| "tumor_mutational_burden_mut_Mb": 14.7, |
| "microsatellite_status": "MSS", |
| "pd_l1_tps_percent": 15 |
| }, |
| "baseline_clinical": { |
| "age": 68, |
| "sex": "female", |
| "bmi": 26.5, |
| "smoking_pack_years": 38, |
| "ecog_performance_status": 0, |
| "comorbidities": [] |
| }, |
| "disease_burden_at_dx": { |
| "primary_tumor_size_cm": 7.2, |
| "metastatic_sites": [ |
| "bone", |
| "pleura" |
| ], |
| "brain_metastases_present": false, |
| "radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease." |
| }, |
| "treatment_course": { |
| "first_line_therapy": { |
| "regimen": "sotorasib 960 mg daily", |
| "start_date": "2021-06-01", |
| "best_response": "Partial response", |
| "radiologic_response": { |
| "first_ct_8wk_change_percent": -15, |
| "peak_response_20wk_change_percent": -27 |
| }, |
| "pfs_months": 16 |
| }, |
| "second_line_therapy": { |
| "trigger_reason": "symptomatic progression", |
| "regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab", |
| "start_date": "2023-09-03", |
| "best_response": "Stable disease", |
| "toxicity_grade": [ |
| "Grade 1 nausea", |
| "Grade 3 neutropenia" |
| ] |
| } |
| }, |
| "survival_outcomes": { |
| "overall_survival_months": 90, |
| "censored": false |
| }, |
| "longitudinal_labs": [ |
| { |
| "date": "2021-05-10", |
| "hemoglobin_g_dL": 15.3, |
| "wbc_k_uL": 8.1, |
| "platelets_k_uL": 158, |
| "creatinine_mg_dL": 1.21, |
| "alt_U_L": 20 |
| }, |
| { |
| "date": "2021-11-28", |
| "hemoglobin_g_dL": 13.6, |
| "wbc_k_uL": 6.3, |
| "platelets_k_uL": 243, |
| "creatinine_mg_dL": 0.96, |
| "alt_U_L": 114 |
| }, |
| { |
| "date": "2023-09-03", |
| "hemoglobin_g_dL": 11.7, |
| "wbc_k_uL": 5.4, |
| "platelets_k_uL": 254, |
| "creatinine_mg_dL": 0.81, |
| "alt_U_L": 200 |
| } |
| ], |
| "synthetic_high_fidelity": true |
| }, |
| { |
| "patient_id": "ANODE_SYNTH_2025_007", |
| "cancer_type": "Non-small cell lung cancer", |
| "histology": "Adenocarcinoma", |
| "stage_at_diagnosis": "IVB", |
| "molecular_profile": { |
| "driver_mutation": "EGFR exon 19 deletion", |
| "t790m_resistance": false, |
| "tumor_mutational_burden_mut_Mb": 9.7, |
| "microsatellite_status": "MSS", |
| "pd_l1_tps_percent": 0 |
| }, |
| "baseline_clinical": { |
| "age": 84, |
| "sex": "female", |
| "bmi": 20.6, |
| "smoking_pack_years": 0, |
| "ecog_performance_status": 0, |
| "comorbidities": [ |
| "hyperlipidemia", |
| "COPD" |
| ] |
| }, |
| "disease_burden_at_dx": { |
| "primary_tumor_size_cm": 3.0, |
| "metastatic_sites": [ |
| "brain" |
| ], |
| "brain_metastases_present": false, |
| "radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present." |
| }, |
| "treatment_course": { |
| "first_line_therapy": { |
| "regimen": "osimertinib 80 mg orally once daily", |
| "start_date": "2021-12-22", |
| "best_response": "Partial response", |
| "radiologic_response": { |
| "first_ct_8wk_change_percent": -45, |
| "peak_response_20wk_change_percent": -54 |
| }, |
| "pfs_months": 20 |
| }, |
| "second_line_therapy": { |
| "trigger_reason": "new brain metastases", |
| "regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab", |
| "start_date": "2023-07-25", |
| "best_response": "Stable disease", |
| "toxicity_grade": [ |
| "Grade 2 fatigue", |
| "Grade 3 neutropenia" |
| ] |
| } |
| }, |
| "survival_outcomes": { |
| "overall_survival_months": 73, |
| "censored": true |
| }, |
| "longitudinal_labs": [ |
| { |
| "date": "2021-11-14", |
| "hemoglobin_g_dL": 12.7, |
| "wbc_k_uL": 10.8, |
| "platelets_k_uL": 228, |
| "creatinine_mg_dL": 1.09, |
| "alt_U_L": 23 |
| }, |
| { |
| "date": "2022-06-20", |
| "hemoglobin_g_dL": 10.7, |
| "wbc_k_uL": 7.6, |
| "platelets_k_uL": 305, |
| "creatinine_mg_dL": 1.59, |
| "alt_U_L": 22 |
| }, |
| { |
| "date": "2023-07-25", |
| "hemoglobin_g_dL": 11.2, |
| "wbc_k_uL": 4.3, |
| "platelets_k_uL": 249, |
| "creatinine_mg_dL": 1.3, |
| "alt_U_L": 196 |
| } |
| ], |
| "synthetic_high_fidelity": true |
| }, |
| { |
| "patient_id": "ANODE_SYNTH_2025_008", |
| "cancer_type": "Non-small cell lung cancer", |
| "histology": "Adenocarcinoma", |
| "stage_at_diagnosis": "IV", |
| "molecular_profile": { |
| "driver_mutation": "None (PD-L1 high)", |
| "t790m_resistance": null, |
| "tumor_mutational_burden_mut_Mb": 9.1, |
| "microsatellite_status": "MSS", |
| "pd_l1_tps_percent": 89 |
| }, |
| "baseline_clinical": { |
| "age": 81, |
| "sex": "female", |
| "bmi": 24.4, |
| "smoking_pack_years": 30, |
| "ecog_performance_status": 1, |
| "comorbidities": [ |
| "COPD" |
| ] |
| }, |
| "disease_burden_at_dx": { |
| "primary_tumor_size_cm": 4.4, |
| "metastatic_sites": [ |
| "adrenal", |
| "liver" |
| ], |
| "brain_metastases_present": false, |
| "radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease." |
| }, |
| "treatment_course": { |
| "first_line_therapy": { |
| "regimen": "pembrolizumab 200 mg q3w", |
| "start_date": "2025-02-18", |
| "best_response": "Partial response", |
| "radiologic_response": { |
| "first_ct_8wk_change_percent": -33, |
| "peak_response_20wk_change_percent": -79 |
| }, |
| "pfs_months": 6 |
| }, |
| "second_line_therapy": { |
| "trigger_reason": "new brain metastases", |
| "regimen": "docetaxel 75 mg/m\u00b2 q21d", |
| "start_date": "2026-11-14", |
| "best_response": "Stable disease", |
| "toxicity_grade": [ |
| "Grade 1 nausea", |
| "Grade 3 neutropenia" |
| ] |
| } |
| }, |
| "survival_outcomes": { |
| "overall_survival_months": 41, |
| "censored": false |
| }, |
| "longitudinal_labs": [ |
| { |
| "date": "2025-01-11", |
| "hemoglobin_g_dL": 15.2, |
| "wbc_k_uL": 7.0, |
| "platelets_k_uL": 245, |
| "creatinine_mg_dL": 1.22, |
| "alt_U_L": 50 |
| }, |
| { |
| "date": "2025-08-17", |
| "hemoglobin_g_dL": 10.3, |
| "wbc_k_uL": 8.8, |
| "platelets_k_uL": 336, |
| "creatinine_mg_dL": 1.39, |
| "alt_U_L": 57 |
| }, |
| { |
| "date": "2026-11-14", |
| "hemoglobin_g_dL": 10.4, |
| "wbc_k_uL": 6.6, |
| "platelets_k_uL": 236, |
| "creatinine_mg_dL": 1.42, |
| "alt_U_L": 145 |
| } |
| ], |
| "synthetic_high_fidelity": true |
| }, |
| { |
| "patient_id": "ANODE_SYNTH_2025_009", |
| "cancer_type": "Non-small cell lung cancer", |
| "histology": "Adenocarcinoma", |
| "stage_at_diagnosis": "IV", |
| "molecular_profile": { |
| "driver_mutation": "KRAS G12C", |
| "t790m_resistance": null, |
| "tumor_mutational_burden_mut_Mb": 10.2, |
| "microsatellite_status": "MSS", |
| "pd_l1_tps_percent": 22 |
| }, |
| "baseline_clinical": { |
| "age": 82, |
| "sex": "female", |
| "bmi": 33.9, |
| "smoking_pack_years": 22, |
| "ecog_performance_status": 2, |
| "comorbidities": [] |
| }, |
| "disease_burden_at_dx": { |
| "primary_tumor_size_cm": 5.5, |
| "metastatic_sites": [ |
| "pleura", |
| "adrenal" |
| ], |
| "brain_metastases_present": false, |
| "radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease." |
| }, |
| "treatment_course": { |
| "first_line_therapy": { |
| "regimen": "sotorasib 960 mg daily", |
| "start_date": "2024-06-13", |
| "best_response": "Partial response", |
| "radiologic_response": { |
| "first_ct_8wk_change_percent": -58, |
| "peak_response_20wk_change_percent": -41 |
| }, |
| "pfs_months": 17 |
| }, |
| "second_line_therapy": { |
| "trigger_reason": "new brain metastases", |
| "regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab", |
| "start_date": "2026-03-28", |
| "best_response": "Stable disease", |
| "toxicity_grade": [ |
| "Grade 1 nausea", |
| "none" |
| ] |
| } |
| }, |
| "survival_outcomes": { |
| "overall_survival_months": 34, |
| "censored": true |
| }, |
| "longitudinal_labs": [ |
| { |
| "date": "2024-05-16", |
| "hemoglobin_g_dL": 12.7, |
| "wbc_k_uL": 10.5, |
| "platelets_k_uL": 388, |
| "creatinine_mg_dL": 0.87, |
| "alt_U_L": 72 |
| }, |
| { |
| "date": "2024-12-10", |
| "hemoglobin_g_dL": 13.4, |
| "wbc_k_uL": 4.0, |
| "platelets_k_uL": 349, |
| "creatinine_mg_dL": 0.77, |
| "alt_U_L": 108 |
| }, |
| { |
| "date": "2026-03-28", |
| "hemoglobin_g_dL": 11.0, |
| "wbc_k_uL": 6.1, |
| "platelets_k_uL": 198, |
| "creatinine_mg_dL": 0.97, |
| "alt_U_L": 144 |
| } |
| ], |
| "synthetic_high_fidelity": true |
| }, |
| { |
| "patient_id": "ANODE_SYNTH_2025_010", |
| "cancer_type": "Non-small cell lung cancer", |
| "histology": "Adenocarcinoma", |
| "stage_at_diagnosis": "IVB", |
| "molecular_profile": { |
| "driver_mutation": "EGFR L858R", |
| "t790m_resistance": false, |
| "tumor_mutational_burden_mut_Mb": 7.2, |
| "microsatellite_status": "MSS", |
| "pd_l1_tps_percent": 5 |
| }, |
| "baseline_clinical": { |
| "age": 83, |
| "sex": "female", |
| "bmi": 30.3, |
| "smoking_pack_years": 0, |
| "ecog_performance_status": 1, |
| "comorbidities": [ |
| "diabetes" |
| ] |
| }, |
| "disease_burden_at_dx": { |
| "primary_tumor_size_cm": 4.7, |
| "metastatic_sites": [ |
| "brain" |
| ], |
| "brain_metastases_present": false, |
| "radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease." |
| }, |
| "treatment_course": { |
| "first_line_therapy": { |
| "regimen": "osimertinib 80 mg orally once daily", |
| "start_date": "2021-03-10", |
| "best_response": "Partial response", |
| "radiologic_response": { |
| "first_ct_8wk_change_percent": -16, |
| "peak_response_20wk_change_percent": -55 |
| }, |
| "pfs_months": 15 |
| }, |
| "second_line_therapy": { |
| "trigger_reason": "new brain metastases", |
| "regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab", |
| "start_date": "2023-05-14", |
| "best_response": "Stable disease", |
| "toxicity_grade": [ |
| "none", |
| "Grade 2 fatigue" |
| ] |
| } |
| }, |
| "survival_outcomes": { |
| "overall_survival_months": 70, |
| "censored": false |
| }, |
| "longitudinal_labs": [ |
| { |
| "date": "2021-01-12", |
| "hemoglobin_g_dL": 14.1, |
| "wbc_k_uL": 7.5, |
| "platelets_k_uL": 221, |
| "creatinine_mg_dL": 0.81, |
| "alt_U_L": 60 |
| }, |
| { |
| "date": "2021-09-06", |
| "hemoglobin_g_dL": 10.8, |
| "wbc_k_uL": 9.0, |
| "platelets_k_uL": 317, |
| "creatinine_mg_dL": 1.09, |
| "alt_U_L": 49 |
| }, |
| { |
| "date": "2023-05-14", |
| "hemoglobin_g_dL": 12.8, |
| "wbc_k_uL": 5.8, |
| "platelets_k_uL": 276, |
| "creatinine_mg_dL": 0.8, |
| "alt_U_L": 109 |
| } |
| ], |
| "synthetic_high_fidelity": true |
| }, |
| { |
| "patient_id": "ANODE_SYNTH_2025_011", |
| "cancer_type": "Non-small cell lung cancer", |
| "histology": "Adenocarcinoma", |
| "stage_at_diagnosis": "IVB", |
| "molecular_profile": { |
| "driver_mutation": "EGFR exon 19 deletion", |
| "t790m_resistance": false, |
| "tumor_mutational_burden_mut_Mb": 2.6, |
| "microsatellite_status": "MSS", |
| "pd_l1_tps_percent": 23 |
| }, |
| "baseline_clinical": { |
| "age": 49, |
| "sex": "female", |
| "bmi": 31.1, |
| "smoking_pack_years": 0, |
| "ecog_performance_status": 1, |
| "comorbidities": [] |
| }, |
| "disease_burden_at_dx": { |
| "primary_tumor_size_cm": 3.1, |
| "metastatic_sites": [ |
| "pleura", |
| "bone" |
| ], |
| "brain_metastases_present": false, |
| "radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present." |
| }, |
| "treatment_course": { |
| "first_line_therapy": { |
| "regimen": "osimertinib 80 mg orally once daily", |
| "start_date": "2023-07-12", |
| "best_response": "Partial response", |
| "radiologic_response": { |
| "first_ct_8wk_change_percent": -45, |
| "peak_response_20wk_change_percent": -22 |
| }, |
| "pfs_months": 18 |
| }, |
| "second_line_therapy": { |
| "trigger_reason": "radiologic progression", |
| "regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab", |
| "start_date": "2025-01-05", |
| "best_response": "Stable disease", |
| "toxicity_grade": [ |
| "Grade 1 nausea", |
| "Grade 3 neutropenia" |
| ] |
| } |
| }, |
| "survival_outcomes": { |
| "overall_survival_months": 46, |
| "censored": false |
| }, |
| "longitudinal_labs": [ |
| { |
| "date": "2023-06-22", |
| "hemoglobin_g_dL": 14.1, |
| "wbc_k_uL": 4.8, |
| "platelets_k_uL": 314, |
| "creatinine_mg_dL": 1.03, |
| "alt_U_L": 13 |
| }, |
| { |
| "date": "2024-01-08", |
| "hemoglobin_g_dL": 10.6, |
| "wbc_k_uL": 6.9, |
| "platelets_k_uL": 237, |
| "creatinine_mg_dL": 1.42, |
| "alt_U_L": 44 |
| }, |
| { |
| "date": "2025-01-05", |
| "hemoglobin_g_dL": 12.4, |
| "wbc_k_uL": 4.6, |
| "platelets_k_uL": 171, |
| "creatinine_mg_dL": 1.41, |
| "alt_U_L": 119 |
| } |
| ], |
| "synthetic_high_fidelity": true |
| }, |
| { |
| "patient_id": "ANODE_SYNTH_2025_012", |
| "cancer_type": "Non-small cell lung cancer", |
| "histology": "Adenocarcinoma", |
| "stage_at_diagnosis": "IV", |
| "molecular_profile": { |
| "driver_mutation": "BRAF V600E", |
| "t790m_resistance": null, |
| "tumor_mutational_burden_mut_Mb": 4.5, |
| "microsatellite_status": "MSS", |
| "pd_l1_tps_percent": 17 |
| }, |
| "baseline_clinical": { |
| "age": 74, |
| "sex": "female", |
| "bmi": 22.3, |
| "smoking_pack_years": 17, |
| "ecog_performance_status": 1, |
| "comorbidities": [ |
| "hyperlipidemia" |
| ] |
| }, |
| "disease_burden_at_dx": { |
| "primary_tumor_size_cm": 7.9, |
| "metastatic_sites": [ |
| "liver" |
| ], |
| "brain_metastases_present": false, |
| "radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease." |
| }, |
| "treatment_course": { |
| "first_line_therapy": { |
| "regimen": "carboplatin + pemetrexed + pembrolizumab", |
| "start_date": "2023-12-16", |
| "best_response": "Partial response", |
| "radiologic_response": { |
| "first_ct_8wk_change_percent": -41, |
| "peak_response_20wk_change_percent": -51 |
| }, |
| "pfs_months": 13 |
| }, |
| "second_line_therapy": { |
| "trigger_reason": "new brain metastases", |
| "regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab", |
| "start_date": "2025-06-06", |
| "best_response": "Stable disease", |
| "toxicity_grade": [ |
| "Grade 1 nausea", |
| "none" |
| ] |
| } |
| }, |
| "survival_outcomes": { |
| "overall_survival_months": 46, |
| "censored": false |
| }, |
| "longitudinal_labs": [ |
| { |
| "date": "2023-11-18", |
| "hemoglobin_g_dL": 15.3, |
| "wbc_k_uL": 10.6, |
| "platelets_k_uL": 182, |
| "creatinine_mg_dL": 0.75, |
| "alt_U_L": 62 |
| }, |
| { |
| "date": "2024-06-13", |
| "hemoglobin_g_dL": 11.5, |
| "wbc_k_uL": 7.5, |
| "platelets_k_uL": 316, |
| "creatinine_mg_dL": 0.81, |
| "alt_U_L": 93 |
| }, |
| { |
| "date": "2025-06-06", |
| "hemoglobin_g_dL": 12.8, |
| "wbc_k_uL": 7.4, |
| "platelets_k_uL": 287, |
| "creatinine_mg_dL": 1.53, |
| "alt_U_L": 156 |
| } |
| ], |
| "synthetic_high_fidelity": true |
| }, |
| { |
| "patient_id": "ANODE_SYNTH_2025_013", |
| "cancer_type": "Non-small cell lung cancer", |
| "histology": "Adenocarcinoma", |
| "stage_at_diagnosis": "IVB", |
| "molecular_profile": { |
| "driver_mutation": "ALK fusion", |
| "t790m_resistance": null, |
| "tumor_mutational_burden_mut_Mb": 1.9, |
| "microsatellite_status": "MSS", |
| "pd_l1_tps_percent": 7 |
| }, |
| "baseline_clinical": { |
| "age": 68, |
| "sex": "male", |
| "bmi": 29.1, |
| "smoking_pack_years": 0, |
| "ecog_performance_status": 1, |
| "comorbidities": [ |
| "hypertension" |
| ] |
| }, |
| "disease_burden_at_dx": { |
| "primary_tumor_size_cm": 4.5, |
| "metastatic_sites": [ |
| "adrenal", |
| "bone" |
| ], |
| "brain_metastases_present": true, |
| "radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present." |
| }, |
| "treatment_course": { |
| "first_line_therapy": { |
| "regimen": "alectinib 600 mg BID", |
| "start_date": "2024-06-22", |
| "best_response": "Partial response", |
| "radiologic_response": { |
| "first_ct_8wk_change_percent": -34, |
| "peak_response_20wk_change_percent": -23 |
| }, |
| "pfs_months": 30 |
| }, |
| "second_line_therapy": { |
| "trigger_reason": "symptomatic progression", |
| "regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab", |
| "start_date": "2026-10-05", |
| "best_response": "Stable disease", |
| "toxicity_grade": [ |
| "none", |
| "Grade 3 neutropenia" |
| ] |
| } |
| }, |
| "survival_outcomes": { |
| "overall_survival_months": 69, |
| "censored": false |
| }, |
| "longitudinal_labs": [ |
| { |
| "date": "2024-04-27", |
| "hemoglobin_g_dL": 12.6, |
| "wbc_k_uL": 9.8, |
| "platelets_k_uL": 220, |
| "creatinine_mg_dL": 0.68, |
| "alt_U_L": 35 |
| }, |
| { |
| "date": "2024-12-19", |
| "hemoglobin_g_dL": 12.5, |
| "wbc_k_uL": 7.2, |
| "platelets_k_uL": 194, |
| "creatinine_mg_dL": 1.49, |
| "alt_U_L": 24 |
| }, |
| { |
| "date": "2026-10-05", |
| "hemoglobin_g_dL": 13.0, |
| "wbc_k_uL": 5.9, |
| "platelets_k_uL": 162, |
| "creatinine_mg_dL": 1.41, |
| "alt_U_L": 30 |
| } |
| ], |
| "synthetic_high_fidelity": true |
| }, |
| { |
| "patient_id": "ANODE_SYNTH_2025_014", |
| "cancer_type": "Non-small cell lung cancer", |
| "histology": "Adenocarcinoma", |
| "stage_at_diagnosis": "IVB", |
| "molecular_profile": { |
| "driver_mutation": "EGFR exon 19 deletion", |
| "t790m_resistance": false, |
| "tumor_mutational_burden_mut_Mb": 15.5, |
| "microsatellite_status": "MSS", |
| "pd_l1_tps_percent": 15 |
| }, |
| "baseline_clinical": { |
| "age": 69, |
| "sex": "female", |
| "bmi": 24.9, |
| "smoking_pack_years": 0, |
| "ecog_performance_status": 0, |
| "comorbidities": [] |
| }, |
| "disease_burden_at_dx": { |
| "primary_tumor_size_cm": 4.5, |
| "metastatic_sites": [ |
| "brain", |
| "liver" |
| ], |
| "brain_metastases_present": false, |
| "radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present." |
| }, |
| "treatment_course": { |
| "first_line_therapy": { |
| "regimen": "osimertinib 80 mg orally once daily", |
| "start_date": "2022-09-30", |
| "best_response": "Stable disease", |
| "radiologic_response": { |
| "first_ct_8wk_change_percent": -47, |
| "peak_response_20wk_change_percent": -27 |
| }, |
| "pfs_months": 28 |
| }, |
| "second_line_therapy": { |
| "trigger_reason": "new brain metastases", |
| "regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab", |
| "start_date": "2024-02-01", |
| "best_response": "Stable disease", |
| "toxicity_grade": [ |
| "Grade 1 nausea", |
| "none" |
| ] |
| } |
| }, |
| "survival_outcomes": { |
| "overall_survival_months": 76, |
| "censored": true |
| }, |
| "longitudinal_labs": [ |
| { |
| "date": "2022-08-27", |
| "hemoglobin_g_dL": 15.0, |
| "wbc_k_uL": 10.5, |
| "platelets_k_uL": 251, |
| "creatinine_mg_dL": 1.0, |
| "alt_U_L": 33 |
| }, |
| { |
| "date": "2023-03-29", |
| "hemoglobin_g_dL": 10.5, |
| "wbc_k_uL": 5.9, |
| "platelets_k_uL": 225, |
| "creatinine_mg_dL": 1.08, |
| "alt_U_L": 119 |
| }, |
| { |
| "date": "2024-02-01", |
| "hemoglobin_g_dL": 9.6, |
| "wbc_k_uL": 4.2, |
| "platelets_k_uL": 214, |
| "creatinine_mg_dL": 1.87, |
| "alt_U_L": 151 |
| } |
| ], |
| "synthetic_high_fidelity": true |
| }, |
| { |
| "patient_id": "ANODE_SYNTH_2025_015", |
| "cancer_type": "Non-small cell lung cancer", |
| "histology": "Adenocarcinoma", |
| "stage_at_diagnosis": "IVB", |
| "molecular_profile": { |
| "driver_mutation": "ALK fusion", |
| "t790m_resistance": null, |
| "tumor_mutational_burden_mut_Mb": 8.1, |
| "microsatellite_status": "MSS", |
| "pd_l1_tps_percent": 0 |
| }, |
| "baseline_clinical": { |
| "age": 51, |
| "sex": "female", |
| "bmi": 35.5, |
| "smoking_pack_years": 0, |
| "ecog_performance_status": 0, |
| "comorbidities": [] |
| }, |
| "disease_burden_at_dx": { |
| "primary_tumor_size_cm": 4.7, |
| "metastatic_sites": [ |
| "bone", |
| "adrenal" |
| ], |
| "brain_metastases_present": false, |
| "radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present." |
| }, |
| "treatment_course": { |
| "first_line_therapy": { |
| "regimen": "alectinib 600 mg BID", |
| "start_date": "2021-05-24", |
| "best_response": "Partial response", |
| "radiologic_response": { |
| "first_ct_8wk_change_percent": -49, |
| "peak_response_20wk_change_percent": -23 |
| }, |
| "pfs_months": 36 |
| }, |
| "second_line_therapy": { |
| "trigger_reason": "radiologic progression", |
| "regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab", |
| "start_date": "2022-08-21", |
| "best_response": "Stable disease", |
| "toxicity_grade": [ |
| "Grade 1 nausea", |
| "none" |
| ] |
| } |
| }, |
| "survival_outcomes": { |
| "overall_survival_months": 80, |
| "censored": true |
| }, |
| "longitudinal_labs": [ |
| { |
| "date": "2021-04-10", |
| "hemoglobin_g_dL": 13.0, |
| "wbc_k_uL": 8.1, |
| "platelets_k_uL": 186, |
| "creatinine_mg_dL": 1.19, |
| "alt_U_L": 43 |
| }, |
| { |
| "date": "2021-11-20", |
| "hemoglobin_g_dL": 13.7, |
| "wbc_k_uL": 8.0, |
| "platelets_k_uL": 149, |
| "creatinine_mg_dL": 1.29, |
| "alt_U_L": 118 |
| }, |
| { |
| "date": "2022-08-21", |
| "hemoglobin_g_dL": 12.3, |
| "wbc_k_uL": 6.4, |
| "platelets_k_uL": 220, |
| "creatinine_mg_dL": 1.1, |
| "alt_U_L": 33 |
| } |
| ], |
| "synthetic_high_fidelity": true |
| }, |
| { |
| "patient_id": "ANODE_SYNTH_2025_016", |
| "cancer_type": "Non-small cell lung cancer", |
| "histology": "Adenocarcinoma", |
| "stage_at_diagnosis": "IV", |
| "molecular_profile": { |
| "driver_mutation": "BRAF V600E", |
| "t790m_resistance": null, |
| "tumor_mutational_burden_mut_Mb": 8.0, |
| "microsatellite_status": "MSS", |
| "pd_l1_tps_percent": 20 |
| }, |
| "baseline_clinical": { |
| "age": 70, |
| "sex": "female", |
| "bmi": 20.4, |
| "smoking_pack_years": 56, |
| "ecog_performance_status": 1, |
| "comorbidities": [ |
| "diabetes", |
| "COPD" |
| ] |
| }, |
| "disease_burden_at_dx": { |
| "primary_tumor_size_cm": 7.5, |
| "metastatic_sites": [ |
| "contralateral lung", |
| "liver" |
| ], |
| "brain_metastases_present": false, |
| "radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease." |
| }, |
| "treatment_course": { |
| "first_line_therapy": { |
| "regimen": "carboplatin + pemetrexed + pembrolizumab", |
| "start_date": "2025-10-11", |
| "best_response": "Partial response", |
| "radiologic_response": { |
| "first_ct_8wk_change_percent": -46, |
| "peak_response_20wk_change_percent": -21 |
| }, |
| "pfs_months": 14 |
| }, |
| "second_line_therapy": { |
| "trigger_reason": "symptomatic progression", |
| "regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab", |
| "start_date": "2028-03-16", |
| "best_response": "Stable disease", |
| "toxicity_grade": [ |
| "Grade 2 fatigue", |
| "none" |
| ] |
| } |
| }, |
| "survival_outcomes": { |
| "overall_survival_months": 94, |
| "censored": true |
| }, |
| "longitudinal_labs": [ |
| { |
| "date": "2025-08-12", |
| "hemoglobin_g_dL": 15.0, |
| "wbc_k_uL": 8.6, |
| "platelets_k_uL": 251, |
| "creatinine_mg_dL": 0.79, |
| "alt_U_L": 64 |
| }, |
| { |
| "date": "2026-04-09", |
| "hemoglobin_g_dL": 11.3, |
| "wbc_k_uL": 5.6, |
| "platelets_k_uL": 324, |
| "creatinine_mg_dL": 1.3, |
| "alt_U_L": 45 |
| }, |
| { |
| "date": "2028-03-16", |
| "hemoglobin_g_dL": 10.6, |
| "wbc_k_uL": 5.9, |
| "platelets_k_uL": 319, |
| "creatinine_mg_dL": 1.01, |
| "alt_U_L": 193 |
| } |
| ], |
| "synthetic_high_fidelity": true |
| }, |
| { |
| "patient_id": "ANODE_SYNTH_2025_017", |
| "cancer_type": "Non-small cell lung cancer", |
| "histology": "Adenocarcinoma", |
| "stage_at_diagnosis": "IV", |
| "molecular_profile": { |
| "driver_mutation": "None (PD-L1 high)", |
| "t790m_resistance": null, |
| "tumor_mutational_burden_mut_Mb": 11.8, |
| "microsatellite_status": "MSS", |
| "pd_l1_tps_percent": 0 |
| }, |
| "baseline_clinical": { |
| "age": 66, |
| "sex": "female", |
| "bmi": 31.5, |
| "smoking_pack_years": 23, |
| "ecog_performance_status": 0, |
| "comorbidities": [ |
| "diabetes" |
| ] |
| }, |
| "disease_burden_at_dx": { |
| "primary_tumor_size_cm": 6.6, |
| "metastatic_sites": [ |
| "bone", |
| "pleura" |
| ], |
| "brain_metastases_present": false, |
| "radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease." |
| }, |
| "treatment_course": { |
| "first_line_therapy": { |
| "regimen": "carboplatin + pemetrexed + pembrolizumab", |
| "start_date": "2021-08-13", |
| "best_response": "Partial response", |
| "radiologic_response": { |
| "first_ct_8wk_change_percent": -52, |
| "peak_response_20wk_change_percent": -44 |
| }, |
| "pfs_months": 8 |
| }, |
| "second_line_therapy": { |
| "trigger_reason": "radiologic progression", |
| "regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab", |
| "start_date": "2022-12-22", |
| "best_response": "Stable disease", |
| "toxicity_grade": [ |
| "Grade 3 neutropenia", |
| "Grade 2 fatigue" |
| ] |
| } |
| }, |
| "survival_outcomes": { |
| "overall_survival_months": 89, |
| "censored": true |
| }, |
| "longitudinal_labs": [ |
| { |
| "date": "2021-06-25", |
| "hemoglobin_g_dL": 12.6, |
| "wbc_k_uL": 7.1, |
| "platelets_k_uL": 357, |
| "creatinine_mg_dL": 1.22, |
| "alt_U_L": 26 |
| }, |
| { |
| "date": "2022-02-09", |
| "hemoglobin_g_dL": 11.4, |
| "wbc_k_uL": 4.2, |
| "platelets_k_uL": 186, |
| "creatinine_mg_dL": 1.53, |
| "alt_U_L": 106 |
| }, |
| { |
| "date": "2022-12-22", |
| "hemoglobin_g_dL": 9.7, |
| "wbc_k_uL": 6.3, |
| "platelets_k_uL": 164, |
| "creatinine_mg_dL": 1.87, |
| "alt_U_L": 94 |
| } |
| ], |
| "synthetic_high_fidelity": true |
| }, |
| { |
| "patient_id": "ANODE_SYNTH_2025_018", |
| "cancer_type": "Non-small cell lung cancer", |
| "histology": "Adenocarcinoma", |
| "stage_at_diagnosis": "IV", |
| "molecular_profile": { |
| "driver_mutation": "BRAF V600E", |
| "t790m_resistance": null, |
| "tumor_mutational_burden_mut_Mb": 6.4, |
| "microsatellite_status": "MSS", |
| "pd_l1_tps_percent": 13 |
| }, |
| "baseline_clinical": { |
| "age": 53, |
| "sex": "male", |
| "bmi": 18.7, |
| "smoking_pack_years": 43, |
| "ecog_performance_status": 0, |
| "comorbidities": [] |
| }, |
| "disease_burden_at_dx": { |
| "primary_tumor_size_cm": 7.3, |
| "metastatic_sites": [ |
| "contralateral lung", |
| "bone", |
| "pleura" |
| ], |
| "brain_metastases_present": false, |
| "radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease." |
| }, |
| "treatment_course": { |
| "first_line_therapy": { |
| "regimen": "carboplatin + pemetrexed + pembrolizumab", |
| "start_date": "2024-03-16", |
| "best_response": "Partial response", |
| "radiologic_response": { |
| "first_ct_8wk_change_percent": -37, |
| "peak_response_20wk_change_percent": -61 |
| }, |
| "pfs_months": 17 |
| }, |
| "second_line_therapy": { |
| "trigger_reason": "symptomatic progression", |
| "regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab", |
| "start_date": "2026-03-01", |
| "best_response": "Stable disease", |
| "toxicity_grade": [ |
| "Grade 2 fatigue", |
| "Grade 1 nausea" |
| ] |
| } |
| }, |
| "survival_outcomes": { |
| "overall_survival_months": 41, |
| "censored": true |
| }, |
| "longitudinal_labs": [ |
| { |
| "date": "2024-02-26", |
| "hemoglobin_g_dL": 14.1, |
| "wbc_k_uL": 6.2, |
| "platelets_k_uL": 199, |
| "creatinine_mg_dL": 1.06, |
| "alt_U_L": 62 |
| }, |
| { |
| "date": "2024-09-12", |
| "hemoglobin_g_dL": 10.0, |
| "wbc_k_uL": 5.2, |
| "platelets_k_uL": 225, |
| "creatinine_mg_dL": 1.2, |
| "alt_U_L": 86 |
| }, |
| { |
| "date": "2026-03-01", |
| "hemoglobin_g_dL": 11.1, |
| "wbc_k_uL": 5.2, |
| "platelets_k_uL": 326, |
| "creatinine_mg_dL": 1.32, |
| "alt_U_L": 154 |
| } |
| ], |
| "synthetic_high_fidelity": true |
| }, |
| { |
| "patient_id": "ANODE_SYNTH_2025_019", |
| "cancer_type": "Non-small cell lung cancer", |
| "histology": "Squamous cell", |
| "stage_at_diagnosis": "IV", |
| "molecular_profile": { |
| "driver_mutation": "None (PD-L1 high)", |
| "t790m_resistance": null, |
| "tumor_mutational_burden_mut_Mb": 2.6, |
| "microsatellite_status": "MSS", |
| "pd_l1_tps_percent": 51 |
| }, |
| "baseline_clinical": { |
| "age": 51, |
| "sex": "male", |
| "bmi": 22.2, |
| "smoking_pack_years": 30, |
| "ecog_performance_status": 1, |
| "comorbidities": [] |
| }, |
| "disease_burden_at_dx": { |
| "primary_tumor_size_cm": 4.3, |
| "metastatic_sites": [ |
| "bone", |
| "adrenal" |
| ], |
| "brain_metastases_present": false, |
| "radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease." |
| }, |
| "treatment_course": { |
| "first_line_therapy": { |
| "regimen": "pembrolizumab 200 mg q3w", |
| "start_date": "2022-11-04", |
| "best_response": "Complete response", |
| "radiologic_response": { |
| "first_ct_8wk_change_percent": -21, |
| "peak_response_20wk_change_percent": -66 |
| }, |
| "pfs_months": 8 |
| }, |
| "second_line_therapy": { |
| "trigger_reason": "symptomatic progression", |
| "regimen": "docetaxel 75 mg/m\u00b2 q21d", |
| "start_date": "2025-03-16", |
| "best_response": "Stable disease", |
| "toxicity_grade": [ |
| "Grade 1 nausea", |
| "Grade 2 fatigue" |
| ] |
| } |
| }, |
| "survival_outcomes": { |
| "overall_survival_months": 32, |
| "censored": false |
| }, |
| "longitudinal_labs": [ |
| { |
| "date": "2022-10-06", |
| "hemoglobin_g_dL": 12.2, |
| "wbc_k_uL": 10.6, |
| "platelets_k_uL": 393, |
| "creatinine_mg_dL": 0.88, |
| "alt_U_L": 80 |
| }, |
| { |
| "date": "2023-05-03", |
| "hemoglobin_g_dL": 12.3, |
| "wbc_k_uL": 6.0, |
| "platelets_k_uL": 175, |
| "creatinine_mg_dL": 1.01, |
| "alt_U_L": 32 |
| }, |
| { |
| "date": "2025-03-16", |
| "hemoglobin_g_dL": 11.2, |
| "wbc_k_uL": 3.5, |
| "platelets_k_uL": 157, |
| "creatinine_mg_dL": 0.91, |
| "alt_U_L": 47 |
| } |
| ], |
| "synthetic_high_fidelity": true |
| }, |
| { |
| "patient_id": "ANODE_SYNTH_2025_020", |
| "cancer_type": "Non-small cell lung cancer", |
| "histology": "Adenocarcinoma", |
| "stage_at_diagnosis": "IVB", |
| "molecular_profile": { |
| "driver_mutation": "ALK fusion", |
| "t790m_resistance": null, |
| "tumor_mutational_burden_mut_Mb": 8.1, |
| "microsatellite_status": "MSS", |
| "pd_l1_tps_percent": 3 |
| }, |
| "baseline_clinical": { |
| "age": 52, |
| "sex": "male", |
| "bmi": 34.1, |
| "smoking_pack_years": 0, |
| "ecog_performance_status": 1, |
| "comorbidities": [ |
| "none", |
| "diabetes" |
| ] |
| }, |
| "disease_burden_at_dx": { |
| "primary_tumor_size_cm": 7.3, |
| "metastatic_sites": [ |
| "brain", |
| "pleura", |
| "liver" |
| ], |
| "brain_metastases_present": false, |
| "radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present." |
| }, |
| "treatment_course": { |
| "first_line_therapy": { |
| "regimen": "alectinib 600 mg BID", |
| "start_date": "2024-12-24", |
| "best_response": "Partial response", |
| "radiologic_response": { |
| "first_ct_8wk_change_percent": -29, |
| "peak_response_20wk_change_percent": -61 |
| }, |
| "pfs_months": 38 |
| }, |
| "second_line_therapy": { |
| "trigger_reason": "radiologic progression", |
| "regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab", |
| "start_date": "2026-02-26", |
| "best_response": "Stable disease", |
| "toxicity_grade": [ |
| "Grade 2 fatigue", |
| "none" |
| ] |
| } |
| }, |
| "survival_outcomes": { |
| "overall_survival_months": 64, |
| "censored": false |
| }, |
| "longitudinal_labs": [ |
| { |
| "date": "2024-11-08", |
| "hemoglobin_g_dL": 14.9, |
| "wbc_k_uL": 8.6, |
| "platelets_k_uL": 193, |
| "creatinine_mg_dL": 1.08, |
| "alt_U_L": 38 |
| }, |
| { |
| "date": "2025-06-22", |
| "hemoglobin_g_dL": 11.5, |
| "wbc_k_uL": 7.8, |
| "platelets_k_uL": 237, |
| "creatinine_mg_dL": 1.38, |
| "alt_U_L": 113 |
| }, |
| { |
| "date": "2026-02-26", |
| "hemoglobin_g_dL": 10.7, |
| "wbc_k_uL": 3.2, |
| "platelets_k_uL": 202, |
| "creatinine_mg_dL": 2.0, |
| "alt_U_L": 180 |
| } |
| ], |
| "synthetic_high_fidelity": true |
| }, |
| { |
| "patient_id": "ANODE_SYNTH_2025_021", |
| "cancer_type": "Non-small cell lung cancer", |
| "histology": "Adenocarcinoma", |
| "stage_at_diagnosis": "IV", |
| "molecular_profile": { |
| "driver_mutation": "None (PD-L1 high)", |
| "t790m_resistance": null, |
| "tumor_mutational_burden_mut_Mb": 10.5, |
| "microsatellite_status": "MSS", |
| "pd_l1_tps_percent": 42 |
| }, |
| "baseline_clinical": { |
| "age": 66, |
| "sex": "female", |
| "bmi": 29.3, |
| "smoking_pack_years": 22, |
| "ecog_performance_status": 0, |
| "comorbidities": [ |
| "hypertension" |
| ] |
| }, |
| "disease_burden_at_dx": { |
| "primary_tumor_size_cm": 6.1, |
| "metastatic_sites": [ |
| "adrenal", |
| "bone", |
| "contralateral lung" |
| ], |
| "brain_metastases_present": false, |
| "radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease." |
| }, |
| "treatment_course": { |
| "first_line_therapy": { |
| "regimen": "carboplatin + pemetrexed + pembrolizumab", |
| "start_date": "2024-05-29", |
| "best_response": "Partial response", |
| "radiologic_response": { |
| "first_ct_8wk_change_percent": -59, |
| "peak_response_20wk_change_percent": -76 |
| }, |
| "pfs_months": 7 |
| }, |
| "second_line_therapy": { |
| "trigger_reason": "symptomatic progression", |
| "regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab", |
| "start_date": "2026-03-30", |
| "best_response": "Stable disease", |
| "toxicity_grade": [ |
| "none", |
| "Grade 1 nausea" |
| ] |
| } |
| }, |
| "survival_outcomes": { |
| "overall_survival_months": 87, |
| "censored": false |
| }, |
| "longitudinal_labs": [ |
| { |
| "date": "2024-05-04", |
| "hemoglobin_g_dL": 14.2, |
| "wbc_k_uL": 6.0, |
| "platelets_k_uL": 316, |
| "creatinine_mg_dL": 1.09, |
| "alt_U_L": 54 |
| }, |
| { |
| "date": "2024-11-25", |
| "hemoglobin_g_dL": 12.4, |
| "wbc_k_uL": 4.6, |
| "platelets_k_uL": 253, |
| "creatinine_mg_dL": 1.25, |
| "alt_U_L": 32 |
| }, |
| { |
| "date": "2026-03-30", |
| "hemoglobin_g_dL": 11.4, |
| "wbc_k_uL": 5.5, |
| "platelets_k_uL": 243, |
| "creatinine_mg_dL": 1.32, |
| "alt_U_L": 151 |
| } |
| ], |
| "synthetic_high_fidelity": true |
| }, |
| { |
| "patient_id": "ANODE_SYNTH_2025_022", |
| "cancer_type": "Non-small cell lung cancer", |
| "histology": "Adenocarcinoma", |
| "stage_at_diagnosis": "IV", |
| "molecular_profile": { |
| "driver_mutation": "ROS1 fusion", |
| "t790m_resistance": null, |
| "tumor_mutational_burden_mut_Mb": 16.1, |
| "microsatellite_status": "MSS", |
| "pd_l1_tps_percent": 1 |
| }, |
| "baseline_clinical": { |
| "age": 68, |
| "sex": "male", |
| "bmi": 37.8, |
| "smoking_pack_years": 12, |
| "ecog_performance_status": 1, |
| "comorbidities": [ |
| "none" |
| ] |
| }, |
| "disease_burden_at_dx": { |
| "primary_tumor_size_cm": 3.6, |
| "metastatic_sites": [ |
| "pleura", |
| "liver" |
| ], |
| "brain_metastases_present": false, |
| "radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease." |
| }, |
| "treatment_course": { |
| "first_line_therapy": { |
| "regimen": "carboplatin + pemetrexed + pembrolizumab", |
| "start_date": "2025-10-01", |
| "best_response": "Partial response", |
| "radiologic_response": { |
| "first_ct_8wk_change_percent": -31, |
| "peak_response_20wk_change_percent": -26 |
| }, |
| "pfs_months": 17 |
| }, |
| "second_line_therapy": { |
| "trigger_reason": "symptomatic progression", |
| "regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab", |
| "start_date": "2027-12-28", |
| "best_response": "Stable disease", |
| "toxicity_grade": [ |
| "Grade 3 neutropenia", |
| "Grade 2 fatigue" |
| ] |
| } |
| }, |
| "survival_outcomes": { |
| "overall_survival_months": 53, |
| "censored": false |
| }, |
| "longitudinal_labs": [ |
| { |
| "date": "2025-08-04", |
| "hemoglobin_g_dL": 15.1, |
| "wbc_k_uL": 9.4, |
| "platelets_k_uL": 174, |
| "creatinine_mg_dL": 1.2, |
| "alt_U_L": 11 |
| }, |
| { |
| "date": "2026-03-30", |
| "hemoglobin_g_dL": 13.3, |
| "wbc_k_uL": 7.4, |
| "platelets_k_uL": 234, |
| "creatinine_mg_dL": 1.24, |
| "alt_U_L": 48 |
| }, |
| { |
| "date": "2027-12-28", |
| "hemoglobin_g_dL": 11.1, |
| "wbc_k_uL": 4.9, |
| "platelets_k_uL": 143, |
| "creatinine_mg_dL": 1.09, |
| "alt_U_L": 187 |
| } |
| ], |
| "synthetic_high_fidelity": true |
| }, |
| { |
| "patient_id": "ANODE_SYNTH_2025_023", |
| "cancer_type": "Non-small cell lung cancer", |
| "histology": "Adenocarcinoma", |
| "stage_at_diagnosis": "IVB", |
| "molecular_profile": { |
| "driver_mutation": "ALK fusion", |
| "t790m_resistance": null, |
| "tumor_mutational_burden_mut_Mb": 13.1, |
| "microsatellite_status": "MSS", |
| "pd_l1_tps_percent": 16 |
| }, |
| "baseline_clinical": { |
| "age": 51, |
| "sex": "male", |
| "bmi": 33.8, |
| "smoking_pack_years": 0, |
| "ecog_performance_status": 1, |
| "comorbidities": [] |
| }, |
| "disease_burden_at_dx": { |
| "primary_tumor_size_cm": 4.9, |
| "metastatic_sites": [ |
| "contralateral lung", |
| "liver" |
| ], |
| "brain_metastases_present": true, |
| "radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present." |
| }, |
| "treatment_course": { |
| "first_line_therapy": { |
| "regimen": "alectinib 600 mg BID", |
| "start_date": "2021-09-06", |
| "best_response": "Stable disease", |
| "radiologic_response": { |
| "first_ct_8wk_change_percent": -50, |
| "peak_response_20wk_change_percent": -58 |
| }, |
| "pfs_months": 16 |
| }, |
| "second_line_therapy": { |
| "trigger_reason": "symptomatic progression", |
| "regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab", |
| "start_date": "2023-12-19", |
| "best_response": "Stable disease", |
| "toxicity_grade": [ |
| "Grade 1 nausea", |
| "none" |
| ] |
| } |
| }, |
| "survival_outcomes": { |
| "overall_survival_months": 60, |
| "censored": false |
| }, |
| "longitudinal_labs": [ |
| { |
| "date": "2021-08-20", |
| "hemoglobin_g_dL": 14.9, |
| "wbc_k_uL": 4.8, |
| "platelets_k_uL": 273, |
| "creatinine_mg_dL": 0.97, |
| "alt_U_L": 40 |
| }, |
| { |
| "date": "2022-03-05", |
| "hemoglobin_g_dL": 11.7, |
| "wbc_k_uL": 8.3, |
| "platelets_k_uL": 334, |
| "creatinine_mg_dL": 1.38, |
| "alt_U_L": 34 |
| }, |
| { |
| "date": "2023-12-19", |
| "hemoglobin_g_dL": 11.4, |
| "wbc_k_uL": 6.3, |
| "platelets_k_uL": 116, |
| "creatinine_mg_dL": 1.53, |
| "alt_U_L": 178 |
| } |
| ], |
| "synthetic_high_fidelity": true |
| }, |
| { |
| "patient_id": "ANODE_SYNTH_2025_024", |
| "cancer_type": "Non-small cell lung cancer", |
| "histology": "Adenocarcinoma", |
| "stage_at_diagnosis": "IVB", |
| "molecular_profile": { |
| "driver_mutation": "ALK fusion", |
| "t790m_resistance": null, |
| "tumor_mutational_burden_mut_Mb": 4.2, |
| "microsatellite_status": "MSS", |
| "pd_l1_tps_percent": 22 |
| }, |
| "baseline_clinical": { |
| "age": 62, |
| "sex": "male", |
| "bmi": 33.8, |
| "smoking_pack_years": 0, |
| "ecog_performance_status": 1, |
| "comorbidities": [ |
| "none", |
| "hypertension" |
| ] |
| }, |
| "disease_burden_at_dx": { |
| "primary_tumor_size_cm": 3.7, |
| "metastatic_sites": [ |
| "contralateral lung", |
| "bone" |
| ], |
| "brain_metastases_present": false, |
| "radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present." |
| }, |
| "treatment_course": { |
| "first_line_therapy": { |
| "regimen": "alectinib 600 mg BID", |
| "start_date": "2022-01-08", |
| "best_response": "Partial response", |
| "radiologic_response": { |
| "first_ct_8wk_change_percent": -15, |
| "peak_response_20wk_change_percent": -60 |
| }, |
| "pfs_months": 29 |
| }, |
| "second_line_therapy": { |
| "trigger_reason": "symptomatic progression", |
| "regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab", |
| "start_date": "2023-11-14", |
| "best_response": "Stable disease", |
| "toxicity_grade": [ |
| "Grade 3 neutropenia", |
| "none" |
| ] |
| } |
| }, |
| "survival_outcomes": { |
| "overall_survival_months": 36, |
| "censored": true |
| }, |
| "longitudinal_labs": [ |
| { |
| "date": "2021-11-13", |
| "hemoglobin_g_dL": 12.9, |
| "wbc_k_uL": 9.0, |
| "platelets_k_uL": 267, |
| "creatinine_mg_dL": 0.73, |
| "alt_U_L": 16 |
| }, |
| { |
| "date": "2022-07-07", |
| "hemoglobin_g_dL": 11.0, |
| "wbc_k_uL": 7.4, |
| "platelets_k_uL": 136, |
| "creatinine_mg_dL": 0.75, |
| "alt_U_L": 62 |
| }, |
| { |
| "date": "2023-11-14", |
| "hemoglobin_g_dL": 10.3, |
| "wbc_k_uL": 7.5, |
| "platelets_k_uL": 231, |
| "creatinine_mg_dL": 1.66, |
| "alt_U_L": 23 |
| } |
| ], |
| "synthetic_high_fidelity": true |
| }, |
| { |
| "patient_id": "ANODE_SYNTH_2025_025", |
| "cancer_type": "Non-small cell lung cancer", |
| "histology": "Adenocarcinoma", |
| "stage_at_diagnosis": "IV", |
| "molecular_profile": { |
| "driver_mutation": "ROS1 fusion", |
| "t790m_resistance": null, |
| "tumor_mutational_burden_mut_Mb": 6.3, |
| "microsatellite_status": "MSS", |
| "pd_l1_tps_percent": 19 |
| }, |
| "baseline_clinical": { |
| "age": 64, |
| "sex": "male", |
| "bmi": 27.2, |
| "smoking_pack_years": 26, |
| "ecog_performance_status": 2, |
| "comorbidities": [ |
| "COPD" |
| ] |
| }, |
| "disease_burden_at_dx": { |
| "primary_tumor_size_cm": 7.5, |
| "metastatic_sites": [ |
| "pleura", |
| "adrenal", |
| "brain" |
| ], |
| "brain_metastases_present": false, |
| "radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease." |
| }, |
| "treatment_course": { |
| "first_line_therapy": { |
| "regimen": "carboplatin + pemetrexed + pembrolizumab", |
| "start_date": "2022-05-26", |
| "best_response": "Complete response", |
| "radiologic_response": { |
| "first_ct_8wk_change_percent": -27, |
| "peak_response_20wk_change_percent": -26 |
| }, |
| "pfs_months": 13 |
| }, |
| "second_line_therapy": { |
| "trigger_reason": "symptomatic progression", |
| "regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab", |
| "start_date": "2023-09-21", |
| "best_response": "Stable disease", |
| "toxicity_grade": [ |
| "Grade 1 nausea", |
| "Grade 2 fatigue" |
| ] |
| } |
| }, |
| "survival_outcomes": { |
| "overall_survival_months": 40, |
| "censored": true |
| }, |
| "longitudinal_labs": [ |
| { |
| "date": "2022-04-05", |
| "hemoglobin_g_dL": 14.1, |
| "wbc_k_uL": 7.1, |
| "platelets_k_uL": 382, |
| "creatinine_mg_dL": 1.07, |
| "alt_U_L": 29 |
| }, |
| { |
| "date": "2022-11-22", |
| "hemoglobin_g_dL": 12.2, |
| "wbc_k_uL": 6.3, |
| "platelets_k_uL": 233, |
| "creatinine_mg_dL": 1.38, |
| "alt_U_L": 36 |
| }, |
| { |
| "date": "2023-09-21", |
| "hemoglobin_g_dL": 11.8, |
| "wbc_k_uL": 7.3, |
| "platelets_k_uL": 238, |
| "creatinine_mg_dL": 1.97, |
| "alt_U_L": 67 |
| } |
| ], |
| "synthetic_high_fidelity": true |
| }, |
| { |
| "patient_id": "ANODE_SYNTH_2025_026", |
| "cancer_type": "Non-small cell lung cancer", |
| "histology": "Adenocarcinoma", |
| "stage_at_diagnosis": "IVB", |
| "molecular_profile": { |
| "driver_mutation": "ALK fusion", |
| "t790m_resistance": null, |
| "tumor_mutational_burden_mut_Mb": 8.3, |
| "microsatellite_status": "MSS", |
| "pd_l1_tps_percent": 24 |
| }, |
| "baseline_clinical": { |
| "age": 81, |
| "sex": "female", |
| "bmi": 22.8, |
| "smoking_pack_years": 0, |
| "ecog_performance_status": 1, |
| "comorbidities": [ |
| "COPD" |
| ] |
| }, |
| "disease_burden_at_dx": { |
| "primary_tumor_size_cm": 6.2, |
| "metastatic_sites": [ |
| "liver", |
| "adrenal", |
| "brain" |
| ], |
| "brain_metastases_present": false, |
| "radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present." |
| }, |
| "treatment_course": { |
| "first_line_therapy": { |
| "regimen": "alectinib 600 mg BID", |
| "start_date": "2022-11-29", |
| "best_response": "Partial response", |
| "radiologic_response": { |
| "first_ct_8wk_change_percent": -16, |
| "peak_response_20wk_change_percent": -43 |
| }, |
| "pfs_months": 30 |
| }, |
| "second_line_therapy": { |
| "trigger_reason": "radiologic progression", |
| "regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab", |
| "start_date": "2024-04-15", |
| "best_response": "Stable disease", |
| "toxicity_grade": [ |
| "none", |
| "Grade 3 neutropenia" |
| ] |
| } |
| }, |
| "survival_outcomes": { |
| "overall_survival_months": 68, |
| "censored": false |
| }, |
| "longitudinal_labs": [ |
| { |
| "date": "2022-10-03", |
| "hemoglobin_g_dL": 14.3, |
| "wbc_k_uL": 7.0, |
| "platelets_k_uL": 199, |
| "creatinine_mg_dL": 0.84, |
| "alt_U_L": 77 |
| }, |
| { |
| "date": "2023-05-28", |
| "hemoglobin_g_dL": 13.4, |
| "wbc_k_uL": 8.8, |
| "platelets_k_uL": 225, |
| "creatinine_mg_dL": 1.33, |
| "alt_U_L": 86 |
| }, |
| { |
| "date": "2024-04-15", |
| "hemoglobin_g_dL": 12.8, |
| "wbc_k_uL": 7.0, |
| "platelets_k_uL": 277, |
| "creatinine_mg_dL": 1.91, |
| "alt_U_L": 112 |
| } |
| ], |
| "synthetic_high_fidelity": true |
| }, |
| { |
| "patient_id": "ANODE_SYNTH_2025_027", |
| "cancer_type": "Non-small cell lung cancer", |
| "histology": "Adenocarcinoma", |
| "stage_at_diagnosis": "IVB", |
| "molecular_profile": { |
| "driver_mutation": "ALK fusion", |
| "t790m_resistance": null, |
| "tumor_mutational_burden_mut_Mb": 8.8, |
| "microsatellite_status": "MSS", |
| "pd_l1_tps_percent": 6 |
| }, |
| "baseline_clinical": { |
| "age": 51, |
| "sex": "female", |
| "bmi": 32.6, |
| "smoking_pack_years": 0, |
| "ecog_performance_status": 1, |
| "comorbidities": [ |
| "diabetes", |
| "hyperlipidemia" |
| ] |
| }, |
| "disease_burden_at_dx": { |
| "primary_tumor_size_cm": 8.0, |
| "metastatic_sites": [ |
| "brain", |
| "liver" |
| ], |
| "brain_metastases_present": false, |
| "radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present." |
| }, |
| "treatment_course": { |
| "first_line_therapy": { |
| "regimen": "alectinib 600 mg BID", |
| "start_date": "2024-07-04", |
| "best_response": "Partial response", |
| "radiologic_response": { |
| "first_ct_8wk_change_percent": -60, |
| "peak_response_20wk_change_percent": -33 |
| }, |
| "pfs_months": 32 |
| }, |
| "second_line_therapy": { |
| "trigger_reason": "symptomatic progression", |
| "regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab", |
| "start_date": "2026-08-29", |
| "best_response": "Stable disease", |
| "toxicity_grade": [ |
| "none", |
| "Grade 1 nausea" |
| ] |
| } |
| }, |
| "survival_outcomes": { |
| "overall_survival_months": 94, |
| "censored": false |
| }, |
| "longitudinal_labs": [ |
| { |
| "date": "2024-06-08", |
| "hemoglobin_g_dL": 13.4, |
| "wbc_k_uL": 9.3, |
| "platelets_k_uL": 366, |
| "creatinine_mg_dL": 1.13, |
| "alt_U_L": 12 |
| }, |
| { |
| "date": "2024-12-31", |
| "hemoglobin_g_dL": 10.1, |
| "wbc_k_uL": 4.8, |
| "platelets_k_uL": 132, |
| "creatinine_mg_dL": 1.55, |
| "alt_U_L": 19 |
| }, |
| { |
| "date": "2026-08-29", |
| "hemoglobin_g_dL": 12.6, |
| "wbc_k_uL": 6.0, |
| "platelets_k_uL": 144, |
| "creatinine_mg_dL": 1.49, |
| "alt_U_L": 126 |
| } |
| ], |
| "synthetic_high_fidelity": true |
| }, |
| { |
| "patient_id": "ANODE_SYNTH_2025_028", |
| "cancer_type": "Non-small cell lung cancer", |
| "histology": "Adenocarcinoma", |
| "stage_at_diagnosis": "IV", |
| "molecular_profile": { |
| "driver_mutation": "KRAS G12C", |
| "t790m_resistance": null, |
| "tumor_mutational_burden_mut_Mb": 5.9, |
| "microsatellite_status": "MSS", |
| "pd_l1_tps_percent": 22 |
| }, |
| "baseline_clinical": { |
| "age": 58, |
| "sex": "female", |
| "bmi": 32.1, |
| "smoking_pack_years": 44, |
| "ecog_performance_status": 1, |
| "comorbidities": [ |
| "hypertension", |
| "COPD" |
| ] |
| }, |
| "disease_burden_at_dx": { |
| "primary_tumor_size_cm": 4.1, |
| "metastatic_sites": [ |
| "liver" |
| ], |
| "brain_metastases_present": false, |
| "radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease." |
| }, |
| "treatment_course": { |
| "first_line_therapy": { |
| "regimen": "sotorasib 960 mg daily", |
| "start_date": "2025-01-26", |
| "best_response": "Stable disease", |
| "radiologic_response": { |
| "first_ct_8wk_change_percent": -11, |
| "peak_response_20wk_change_percent": -60 |
| }, |
| "pfs_months": 13 |
| }, |
| "second_line_therapy": { |
| "trigger_reason": "symptomatic progression", |
| "regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab", |
| "start_date": "2026-07-31", |
| "best_response": "Stable disease", |
| "toxicity_grade": [ |
| "Grade 3 neutropenia", |
| "Grade 1 nausea" |
| ] |
| } |
| }, |
| "survival_outcomes": { |
| "overall_survival_months": 60, |
| "censored": false |
| }, |
| "longitudinal_labs": [ |
| { |
| "date": "2024-12-28", |
| "hemoglobin_g_dL": 13.3, |
| "wbc_k_uL": 5.0, |
| "platelets_k_uL": 315, |
| "creatinine_mg_dL": 0.85, |
| "alt_U_L": 33 |
| }, |
| { |
| "date": "2025-07-25", |
| "hemoglobin_g_dL": 10.4, |
| "wbc_k_uL": 5.3, |
| "platelets_k_uL": 177, |
| "creatinine_mg_dL": 1.08, |
| "alt_U_L": 28 |
| }, |
| { |
| "date": "2026-07-31", |
| "hemoglobin_g_dL": 10.8, |
| "wbc_k_uL": 4.8, |
| "platelets_k_uL": 127, |
| "creatinine_mg_dL": 1.76, |
| "alt_U_L": 129 |
| } |
| ], |
| "synthetic_high_fidelity": true |
| }, |
| { |
| "patient_id": "ANODE_SYNTH_2025_029", |
| "cancer_type": "Non-small cell lung cancer", |
| "histology": "Adenocarcinoma", |
| "stage_at_diagnosis": "IVB", |
| "molecular_profile": { |
| "driver_mutation": "EGFR exon 19 deletion", |
| "t790m_resistance": false, |
| "tumor_mutational_burden_mut_Mb": 7.9, |
| "microsatellite_status": "MSS", |
| "pd_l1_tps_percent": 23 |
| }, |
| "baseline_clinical": { |
| "age": 82, |
| "sex": "female", |
| "bmi": 21.7, |
| "smoking_pack_years": 0, |
| "ecog_performance_status": 1, |
| "comorbidities": [ |
| "diabetes" |
| ] |
| }, |
| "disease_burden_at_dx": { |
| "primary_tumor_size_cm": 2.8, |
| "metastatic_sites": [ |
| "pleura", |
| "bone", |
| "contralateral lung" |
| ], |
| "brain_metastases_present": true, |
| "radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present." |
| }, |
| "treatment_course": { |
| "first_line_therapy": { |
| "regimen": "osimertinib 80 mg orally once daily", |
| "start_date": "2021-04-13", |
| "best_response": "Complete response", |
| "radiologic_response": { |
| "first_ct_8wk_change_percent": -43, |
| "peak_response_20wk_change_percent": -53 |
| }, |
| "pfs_months": 34 |
| }, |
| "second_line_therapy": { |
| "trigger_reason": "radiologic progression", |
| "regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab", |
| "start_date": "2023-01-28", |
| "best_response": "Stable disease", |
| "toxicity_grade": [ |
| "none", |
| "Grade 2 fatigue" |
| ] |
| } |
| }, |
| "survival_outcomes": { |
| "overall_survival_months": 28, |
| "censored": true |
| }, |
| "longitudinal_labs": [ |
| { |
| "date": "2021-03-11", |
| "hemoglobin_g_dL": 13.3, |
| "wbc_k_uL": 10.1, |
| "platelets_k_uL": 348, |
| "creatinine_mg_dL": 1.02, |
| "alt_U_L": 46 |
| }, |
| { |
| "date": "2021-10-10", |
| "hemoglobin_g_dL": 11.5, |
| "wbc_k_uL": 4.6, |
| "platelets_k_uL": 372, |
| "creatinine_mg_dL": 0.73, |
| "alt_U_L": 115 |
| }, |
| { |
| "date": "2023-01-28", |
| "hemoglobin_g_dL": 11.3, |
| "wbc_k_uL": 4.7, |
| "platelets_k_uL": 132, |
| "creatinine_mg_dL": 1.95, |
| "alt_U_L": 27 |
| } |
| ], |
| "synthetic_high_fidelity": true |
| }, |
| { |
| "patient_id": "ANODE_SYNTH_2025_030", |
| "cancer_type": "Non-small cell lung cancer", |
| "histology": "Adenocarcinoma", |
| "stage_at_diagnosis": "IV", |
| "molecular_profile": { |
| "driver_mutation": "BRAF V600E", |
| "t790m_resistance": null, |
| "tumor_mutational_burden_mut_Mb": 5.5, |
| "microsatellite_status": "MSS", |
| "pd_l1_tps_percent": 28 |
| }, |
| "baseline_clinical": { |
| "age": 76, |
| "sex": "female", |
| "bmi": 30.9, |
| "smoking_pack_years": 10, |
| "ecog_performance_status": 1, |
| "comorbidities": [ |
| "none", |
| "COPD" |
| ] |
| }, |
| "disease_burden_at_dx": { |
| "primary_tumor_size_cm": 2.8, |
| "metastatic_sites": [ |
| "bone", |
| "liver" |
| ], |
| "brain_metastases_present": false, |
| "radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease." |
| }, |
| "treatment_course": { |
| "first_line_therapy": { |
| "regimen": "carboplatin + pemetrexed + pembrolizumab", |
| "start_date": "2024-06-15", |
| "best_response": "Complete response", |
| "radiologic_response": { |
| "first_ct_8wk_change_percent": -27, |
| "peak_response_20wk_change_percent": -59 |
| }, |
| "pfs_months": 7 |
| }, |
| "second_line_therapy": { |
| "trigger_reason": "symptomatic progression", |
| "regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab", |
| "start_date": "2026-08-04", |
| "best_response": "Stable disease", |
| "toxicity_grade": [ |
| "Grade 3 neutropenia", |
| "none" |
| ] |
| } |
| }, |
| "survival_outcomes": { |
| "overall_survival_months": 95, |
| "censored": false |
| }, |
| "longitudinal_labs": [ |
| { |
| "date": "2024-05-19", |
| "hemoglobin_g_dL": 15.4, |
| "wbc_k_uL": 10.7, |
| "platelets_k_uL": 151, |
| "creatinine_mg_dL": 0.75, |
| "alt_U_L": 37 |
| }, |
| { |
| "date": "2024-12-12", |
| "hemoglobin_g_dL": 11.3, |
| "wbc_k_uL": 7.2, |
| "platelets_k_uL": 302, |
| "creatinine_mg_dL": 0.73, |
| "alt_U_L": 60 |
| }, |
| { |
| "date": "2026-08-04", |
| "hemoglobin_g_dL": 11.5, |
| "wbc_k_uL": 4.7, |
| "platelets_k_uL": 204, |
| "creatinine_mg_dL": 1.09, |
| "alt_U_L": 191 |
| } |
| ], |
| "synthetic_high_fidelity": true |
| } |
| ] |
